Literature DB >> 19707239

Hematology: ESAs to treat anemia--balancing the risks and benefits.

John Glaspy1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19707239     DOI： 10.1038/nrclinonc.2009.126

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

Review 1.  Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis.

Authors:  Julia Bohlius; Simon Langensiepen; Guido Schwarzer; Jerome Seidenfeld; Margaret Piper; Charles Bennett; Andreas Engert
Journal:  J Natl Cancer Inst       Date:  2005-04-06       Impact factor: 13.506

2.  Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

Authors:  Brian Leyland-Jones; Vladimir Semiglazov; Marek Pawlicki; Tadeusz Pienkowski; Sergei Tjulandin; George Manikhas; Antoly Makhson; Anton Roth; David Dodwell; Jose Baselga; Mikhail Biakhov; Konstantinas Valuckas; Edouard Voznyi; Xiangyang Liu; Els Vercammen
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

Review 3.  Erythropoietin or darbepoetin for patients with cancer.

Authors:  J Bohlius; J Wilson; J Seidenfeld; M Piper; G Schwarzer; J Sandercock; S Trelle; O Weingart; S Bayliss; S Brunskill; B Djulbegovic; C L Benett; S Langensiepen; C Hyde; E Engert
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

Review 4.  Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.

Authors:  Julia Bohlius; Jayne Wilson; Jerome Seidenfeld; Margaret Piper; Guido Schwarzer; Josie Sandercock; Sven Trelle; Olaf Weingart; Sue Bayliss; Benjamin Djulbegovic; Charles L Bennett; Simon Langensiepen; Chris Hyde; Andreas Engert
Journal:  J Natl Cancer Inst       Date:  2006-05-17       Impact factor: 13.506

Review 5.  Erythropoietin in cancer patients.

Authors:  John A Glaspy
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

Review 6.  Erythropoiesis-stimulating agents in oncology.

Authors:  John A Glaspy
Journal:  J Natl Compr Canc Netw       Date:  2008-07       Impact factor: 11.908

7.  Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.

Authors:  Robert E Smith; Matti S Aapro; Heinz Ludwig; Tamás Pintér; Martin Smakal; Tudor E Ciuleanu; Li Chen; Tom Lillie; John A Glaspy
Journal:  J Clin Oncol       Date:  2008-01-28       Impact factor: 44.544

8.  Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.

Authors:  Julia Bohlius; Kurt Schmidlin; Corinne Brillant; Guido Schwarzer; Sven Trelle; Jerome Seidenfeld; Marcel Zwahlen; Michael Clarke; Olaf Weingart; Sabine Kluge; Margaret Piper; Dirk Rades; David P Steensma; Benjamin Djulbegovic; Martin F Fey; Isabelle Ray-Coquard; Mitchell Machtay; Volker Moebus; Gillian Thomas; Michael Untch; Martin Schumacher; Matthias Egger; Andreas Engert
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321
  8 in total
  3 in total

1.  Erythropoietin Stimulates Tumor Growth via EphB4.

Authors:  Sunila Pradeep; Jie Huang; Edna M Mora; Alpa M Nick; Min Soon Cho; Sherry Y Wu; Kyunghee Noh; Chad V Pecot; Rajesha Rupaimoole; Martin A Stein; Stephan Brock; Yunfei Wen; Chiyi Xiong; Kshipra Gharpure; Jean M Hansen; Archana S Nagaraja; Rebecca A Previs; Pablo Vivas-Mejia; Hee Dong Han; Wei Hu; Lingegowda S Mangala; Behrouz Zand; Loren J Stagg; John E Ladbury; Bulent Ozpolat; S Neslihan Alpay; Masato Nishimura; Rebecca L Stone; Koji Matsuo; Guillermo N Armaiz-Peña; Heather J Dalton; Christopher Danes; Blake Goodman; Cristian Rodriguez-Aguayo; Carola Kruger; Armin Schneider; Shyon Haghpeykar; Padmavathi Jaladurgam; Mien-Chie Hung; Robert L Coleman; Jinsong Liu; Chun Li; Diana Urbauer; Gabriel Lopez-Berestein; David B Jackson; Anil K Sood
Journal:  Cancer Cell       Date:  2015-10-17       Impact factor: 31.743

2.  Local blockage of self-sustainable erythropoietin signaling suppresses tumor progression in non-small cell lung cancer.

Authors:  Lei He; Shouzhen Wu; Qiang Hao; Elhadji M Dioum; Kuo Zhang; Cun Zhang; Weina Li; Wei Zhang; Yingqi Zhang; Jiming Zhou; Zhijun Pang; Lijuan Zhao; Xiaowen Ma; Meng Li; Qiuyang Zhang
Journal:  Oncotarget       Date:  2017-07-18

3.  AMPKα1 deletion in fibroblasts promotes tumorigenesis in athymic nude mice by p52-mediated elevation of erythropoietin and CDK2.

Authors:  Yanhong Zhou; Hairong Xu; Ye Ding; Qiulun Lu; Ming-Hui Zou; Ping Song
Journal:  Oncotarget       Date:  2016-08-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.